Table 1.

Characteristics of the subjects who donated fibroblast-like synoviocytes for this study

Donor	Diagnosis	Sex	Ethnicity	Disease duration (years)	RF	Medications	Origin of cells	Figures showing which cells were useda
RA-1	RA	Female	White	3	+	NSAID	Asterand Bioscience	1a, b; 2a, b; 3a, b, d
RA-2	RA	Male	Hispanic	<1	+	Prednisone, DMARD	Asterand Bioscience	2a, b; 5a, b, c; 6b
RA-3	RA	Female	White	<1	+	NSAID	Asterand Bioscience	2a, b; 3a, b, d
RA-4	RA	Female	White	12	+	NSAID, prednisone	Asterand Bioscience	1a, b; 2a, b; 4c
RA-5	RA	Female	Hispanic	2	+	DMARD, NSAID	FITDP	1a, b; 4a, b, e, f, g; 5a, b, c
RA-6	RA	Female	White	21	+	Prednisone, DMARD	FITDP	3a, b, c, d
RA-7	RA	Female	White	30	+	Prednisone, DMARD	FITDP	2a, b; 3a, b, c, d; 4c, d, e, f
RA-8	RA	Female	White	20	+	Etanercept, prednisone	FITDP	1a, b; 2a, b
RA-9	RA	Female	White	21	+	Leflunomide, etanercept, prednisone	FITDP	1a, b; 4a, b; 5a, b, c; 6a, b
RA-10	RA	Male	White	15	+	NSAID, prednisone, adalimumab	FITDP	2a, b; 3c; 4c, d, e, f, g
RA-11	RA	Female	African American	11	+	Hydroxychloroquine, prednisone	FITDP	2a, b; 3c; 4c, d, e, f, g
RA-12	RA	Male	White	>10	+	Etanercept	FITDP	1a, b; 3c; 4a, b
RA-13	RA	Female	Hispanic	>10	+	Methotrexate, prednisone	FITDP	3a, b, c, d; 4c, d, e, f; 6a, b
RA-14	RA	Female	White	3	+	Prednisone, methotrexate	FITDP	5a, b, c; 6a, b
OA-1	OA	Female	White	12	−	None	Asterand Bioscience	4c, d, e, f
OA-2	OA	Male	White	16	−	None	Asterand Bioscience	4c, d, e, f
OA-3	OA	Male	White	25	N/A	None	FITDP	4c, d, e, f
OA-4	OA	Male	White	78	N/A	None	FITDP	4c, d, e, f

DMARD disease-modifying antirheumatic drug, FITDP Feinstein Institute Tissue Donation Program, N/A not available, NSAID non-steroidal anti-inflammatory drug, OA osteoarthritis, RA rheumatoid arthritis, RF rheumatoid factor

Patients with RA were 58 ± 10 years old, and patients with OA were 57 ± 5 years old

^aCross-references to figures in this article displaying which cells were used